1.-**44**. (canceled)

45. An antigen-binding molecule which binds to HER3, comprising:

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:45

HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:88

LC-CDR2 having the amino acid sequence of SEQ ID NO:92

LC-CDR3 having the amino acid sequence of SEQ ID NO:95.

46. The antigen-binding molecule according to claim **45**, wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:36; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:83.

47. The antigen-binding molecule according to claim **45**, wherein the antigen-binding molecule further comprises an Fc region.

48. A method of treating or preventing a cancer in a subject, the method comprising administering to a subject a therapeutically or prophylactically effective amount of an antigen-binding molecule which binds to HER3, wherein the antigen-binding molecule comprises:

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:45

HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:88

LC-CDR2 having the amino acid sequence of SEQ ID NO:92

LC-CDR3 having the amino acid sequence of SEQ ID NO:95.

49. The method according to claim **48**, wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:36; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:83.

50. The method according to claim **48**, wherein the cancer is selected from: a HER3-expressing cancer, gastric cancer, head and neck cancer, breast cancer, ovarian cancer, lung cancer, melanoma, prostate cancer, oral cavity cancer, renal cancer or colorectal cancer, oesophageal cancer, pancreatic cancer, a solid cancer and a liquid cancer.

51. The method according to claim **48**, wherein the method further comprises administering an agent capable of inhibiting signalling mediated by an immune checkpoint protein selected from PD-1, CTLA-4, LAG-3, TIM-3, TIGIT and BTLA.

52. A method for killing or reducing the number of HER3-expressing cells, comprising contacting HER3-expressing cells with an antigen-binding molecule which binds to HER3, wherein the antigen-binding molecule comprises:

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:45

HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:88

LC-CDR2 having the amino acid sequence of SEQ ID NO:92

LC-CDR3 having the amino acid sequence of SEQ ID NO:95.

53. The method according to claim **52**, wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:36; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:83.

* * * * *